Pretax income is the income that a company earns before paying income taxes. Cullinan Therapeutics's pretax income for the
three
months ended in Sep. 2024 was $-40.56 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-159.61 Mil.
Cullinan Therapeutics's pretax margin was %.
During the past 6 years, Cullinan Therapeutics's highest Pretax Margin was -356.25%. The lowest was -356.25%. And the median was -356.25%.
Cullinan Therapeutics Pre-Tax Income Historical Data
The historical data trend for Cullinan Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cullinan Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Cullinan Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cullinan Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cullinan Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Cullinan Therapeutics's Pre-Tax Income falls into.
Cullinan Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Cullinan Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-159.61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cullinan Therapeutics (NAS:CGEM) Pre-Tax Income Explanation
Cullinan Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
During the past 6 years, Cullinan Therapeutics's highest Pretax Margin was -356.25%. The lowest was -356.25%. And the median was -356.25%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cullinan Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Cullinan Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CGEM has been successfully added to your 